Parashar Bhupesh, Wernicke A Gabriella, Pavese Al, Singh Prabhsimranjot, Trichter Samuel, Sabbas Albert, Kutler David I, Kuhel William, Port Jeffery L, Lee Paul C, Nori Dattatreyudu, Chao K S Clifford
Department of Radiation Oncology, Weill Cornell Medical Center, New York, NY 10021, USA.
Brachytherapy. 2011 Nov-Dec;10(6):508-13. doi: 10.1016/j.brachy.2011.04.002. Epub 2011 Jun 2.
Cesium-131 ((131)Cs) radioactive seed is Food and Drug Administration approved for permanent seed implant for all cancers, including lung and head and neck (HN) cancers. We describe the first clinical report of (131)Cs dosimetry and exposure rates to treating physicians and staff.
Twenty-eight patients received (131)Cs implant for early stage lung and recurrent HN cancers. A nomogram was developed to calculate the number of seeds needed to cover the wedge line with the prescription dose (80 Gy). Final dosimetry was obtained after CT planning a few days following the surgical procedure. Radiation exposure to the treating physicians and staff was measured at the completion of the procedure.
A nomogram was developed using the variseed software with source data from American Association of Physicists in Medicine TG-43 report. The total volume covered by the prescription isodose line of (131)Cs was measured and compared with (125)I. The prescription volume was smaller for (131)Cs. In addition, the exposure rate with (131)Cs was found to be acceptable.
Our preliminary experience with (131)Cs lung and HN brachytherapy has been very encouraging with excellent dosimetric coverage and acceptable exposure to the treating physicians and staff.
铯 - 131（¹³¹Cs）放射性种子已获美国食品药品监督管理局批准，可用于包括肺癌和头颈部（HN）癌在内的所有癌症的永久性种子植入。我们报告了首例关于¹³¹Cs剂量测定以及对治疗医生和工作人员的照射率的临床报告。
28例患者接受了¹³¹Cs植入，用于早期肺癌和复发性HN癌。制定了一个列线图，以计算用处方剂量（80 Gy）覆盖楔形线所需的种子数量。在手术后几天进行CT规划后获得最终剂量测定结果。在手术结束时测量了对治疗医生和工作人员的辐射暴露。
使用variseed软件并依据美国医学物理学家协会TG - 43报告中的源数据制定了列线图。测量了¹³¹Cs处方等剂量线覆盖的总体积，并与¹²⁵I进行了比较。¹³¹Cs的处方体积较小。此外，发现¹³¹Cs的照射率是可接受的。
我们在¹³¹Cs肺癌和HN近距离放射治疗方面的初步经验非常令人鼓舞，剂量测定覆盖良好，且对治疗医生和工作人员的照射可接受。
